Findings seen for adults aged 65 years and older and for those aged 18 years and older with end-stage renal disease
Bivalent COVID-19 Shot Effective for Preventing Thromboembolic Events
Findings seen for adults aged 65 years and older and for those aged 18 years and older with end-stage renal disease
Low Risk of Recurrent Thrombotic Events After COVID-19-Linked VTE
Risk of recurrent thrombotic events similar to that of patients with VTE linked to hospitalization for other acute medical illness
Venous Thromboembolism Risk Low in COVID-19 Outpatients
Patient-level factors, including age, sex, and body mass index, associated with higher risk
Pooled Risk for Thrombocytopenia Increased After ChAdOx1-S Vaccine
Pooled 30 percent increased risk for thrombocytopenia seen after first dose of ChAdOx1-S versus BNT162b2
Full-Dose Anticoagulation Beneficial for Critically Ill With COVID-19
However, no significant difference seen in efficacy or safety outcomes for clopidogrel versus no antiplatelet therapy
Adenoviral-Based COVID-19 Vaccines May Up Short-Term CV Risk
Increased incidence of myocardial infarction, pulmonary embolism seen in second week after first dose of Oxford-AstraZeneca vaccine
Blood Biomarker Linked to Incident VTE in COVID-19 Patients
Higher levels of soluble urokinase plasminogen activator receptor linked to incident venous thromboembolism independently of D-dimer
Relative Risk for CVT Up After AZD1222 COVID-19 Vaccine
Relative rates of hospital contacts for coagulation disorder, cerebrovascular disease increased after AZD1222 vaccination
FDA Limits Use of J&J COVID-19 Vaccine Due to Blood Clot Risk
With safer two-dose vaccines such as Pfizer and Moderna widely available, the one-dose J&J shot should be limited